Argenica Therapeutics (ASX:AGN) has completed the manufacturing of the ARG-007 drug required for Phase 2 clinical trials. The finalised, sterile drug product manufacturing will be completed by the end of the year keeping the Argenica on track for first patient dosing during Q1 CY24 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231214/pdf/05yjzbqmnd1b00.pdf $AGN #Phase2 #ClinicalTrials #shorts
PET
0.019
171.4%
STP
0.265
-44.2%
CKA
0.073
69.8%
VBS
0.11
-37.1%
A1G
0.52
65.1%
IPB
0.006
-33.3%
APC
0.015
50%
NAE
0.002
-33.3%
AYT
0.006
50%
SFG
0.002
-33.3%
ERA
0.003
50%
OVT
0.005
-28.6%
RMY
0.045
45.2%
VUL
4.41
-27.5%
TCG
0.75
38.9%
IMI
0.011
-26.7%
QFE
0.081
37.3%
CTN
0.003
-25%
PNN
0.12
36.4%
MAY
0.009
-25%
DAL
0.054
35%
RKB
0.003
-25%
DMG
0.008
33.3%
NFM
0.016
-23.8%
FBR
0.004
33.3%
EPI
1.005
-23.3%
MRQ
0.004
33.3%
IBX
0.02
-23.1%
BDG
0.08
29%
RML
0.053
-22.1%
MGA
0.081
28.6%
AUR
0.018
-21.7%
NES
0.009
28.6%
LMG
0.023
-20.7%
GR8
0.205
28.1%
AKN
0.004
-20%
EDU
0.77
27.3%
FCT
0.008
-20%
PKY
0.019
26.7%
GLL
0.008
-20%
